Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 17 January 2013 | By Alexander Gaffney, RAC,
The European Commission (EC) has launched a public consultation on four revised chapters of its good manufacturing practice guidelines, saying a number of changes were necessary to reflect best practices and the latest thinking.
One of the sections set to be revised is GMP Chapter 3, which details ways in which companies should reduce the potential for cross-contamination in facilities that manufacture multiple product lines. Factories should be designed properly to ensure that cross-contamination does not occur, and owners are advised to follow Quality Risk Management principles to assess and controls risks present or inherent in the facility.
"Risk assessment should include among other parameters a toxicological evaluation of the products being manufactured," the chapter notes.
Some facilities, however, will not be permitted to manufacture multiple product lines. Those include cases when cross-contamination cannot be adequately controlled by operational or technical measures, when or if scientific data does not support threshold values, or if threshold values are too difficult to detect.
Chapter 5 expands upon this logic, and EC notes the two should be read in conjunction with a draft European Medicines Agency (EMA) guideline on exposure limits in manufacturing facilities. The chapter contains several new revisions, including refined guidance on where products should and should not be manufactured (i.e. not in the presence of non-medical products) and the use of technical poisons like pesticides or herbicides (don't use them in the presence of medical products).
Sections 26, 27 and 28 of the chapter also explain that suppliers and starting materials will need to be qualified so as to ensure that products are traceable within the supply chain. This will require documentation and supervision to guard against adulteration.
"The supporting evidence for each supplier/material approval should be maintained," EC explained. "Staff involved in these activities should have a current knowledge of the suppliers, the supply chain and the associated risks involved. Where possible, starting materials should be purchased directly from the manufacturer of the starting material."
This logic applies not just to active pharmaceutical ingredients (APIs), but also to excipients which could "pose a particular risk to the quality of the medicinal product," the chapter explains. All starting materials used in the production of medicines should be tested, as should the finished product.
Chapter 6 includes a new section on technical transfer of testing methods as well, which explains that test methods should be verified so that they are the same as those validated in the original marketing authorization dossier. The transfer of this technology between testing facilities needs to be documented and tested to ensure that the technology is the same, operators are adequately trained, standards are maintained and acceptance criteria is established.
Finally, GMP Chapter 8 has undergone revisions to reflect new Quality Risk Management principles for the investigation of defects, complaints and responsibilities. The Chapter is extensive, and includes everything from detailing the receipt of the complaint, its investigation, its analysis, determining its causes, determining how to prevent such defects in the future, and an assessment of recall actions.
All chapters will go into effect on 17 June 2013.
Tags: European Commission, GMP
Regulatory Focus newsletters
All the biggest regulatory news and happenings.